The first poster will highlight the unique structural features of firmonertinib, which enhance its binding and activity against EGFR mutant proteins, including those with exon 20 insertion mutations. This is particularly significant as these mutations are often resistant to existing therapies. The data presented will include high-resolution crystal structure data that supports the ongoing pivotal Phase 3 study of firmonertinib in frontline non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations.
The second poster will detail the preclinical findings for ARR-002, which has demonstrated superior anti-tumor activity in ovarian cancer models compared to single-target or bivalent approaches. The findings suggest that ARR-002 has the potential to be a best-in-class ADC, with favorable tolerability and efficacy, making it a promising candidate for clinical evaluation in ovarian and endometrial cancers.
ArriVent's participation in the AACR Annual Meeting underscores its commitment to advancing innovative therapies for cancer treatment. The company aims to leverage its deep drug development expertise to maximize the potential of its lead candidates, including firmonertinib and ARR-002, as it moves towards clinical trials and eventual commercialization.
